Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Paraganglioma Market Grown from 2024 to 2025?
The market size for paraganglioma has seen substantive growth in recent years. The market expansion will progress from $2.89 billion in 2024 to $3.03 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.0%. This development in the historical era is credited to improvements in diagnostic imaging, rising consciousness and screening programs, approval of targeted therapies by regulators, growth in dedicated treatment centers, and the progression of genetic testing.
What Growth Rate Is Anticipated for the Paraganglioma Market in the Coming Years?
Paraganglioma market is predicted to experience considerable growth in the near future, ballooning to $3.64 billion by 2029 with a CAGR of 4.7%. This market expansion in the projected period is credited to the emergence of innovative targeted and immunotherapies, the growth of radiopharmaceuticals, increasing instances of genetic disease, more investment in rare disease study, and better access to healthcare in developing markets. Key trends for this forecast period encompass advancements in targeted therapies, enlargement of radiopharmaceuticals, the surging interest in immunotherapy strategies, enhancements in AI-driven diagnostics, and the advancement of less invasive surgical procedures.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21245&type=smp
Who Are the Leading Companies in the Paraganglioma Market?
Major companies operating in the paraganglioma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc. , Mount Sinai, Penn Medicine, Stanford Health Care, St. Jude Children’s Research Hospital, UT Health San Antonio, The University of Chicago Medical Center, Fred Hutchinson Cancer Center, Florida Cancer Specialists & Research Institute, Invitae Corp., Clinigen Group plc, Fulgent Genetics, Dana-Farber Cancer Institute Inc., Oncology Hematology Care Inc., Enterome , National Institutes of Health Clinical Center, Progenics Pharmaceuticals Inc., Pheo Para Alliance, Saint John’s Cancer Institute
What Are the Key Drivers of the Paraganglioma Market?
The growth of the paraganglioma market is anticipated to be spurred by escalating investment in cancer research and medicine. Investment in these sectors comes from the likes of governments, pharmaceutical corporations, research bodies, and individual investors, with the aim of boosting the comprehension, avoidance, detection, and treatment of cancer. This increase in investment is a result of the global cancer burden, advancements in precise medicine, a rising demand for innovative treatments, an increase in clinical trials, government and private funding, and the evolution of targeted and immunotherapy treatments. The funding in cancer research and medicine bolsters the paraganglioma market by aiding improvement in early diagnosis, expanding the range of treatment options such as targeted treatments and immunotherapy, financing clinical trials for more potent drugs, advancing pediatric cancer care infrastructure, and encouraging forward-thinking research to better comprehend the disease’s progression and biology. For example, in May 2024, as per the IQVIA, a leading IT firm from India offering advanced analytics, worldwide expense on cancer-related medicine climbed to $223 billion in 2023, showing a $25 billion rise since 2022, and is projected to hit $409 billion by 2028. Thus, the mounting investments in cancer research and medicine are fuelling the paraganglioma market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21245&type=smp
What Are the Key Market Segments in the Paraganglioma Industry?
The paraganglioma market covered in this report is segmented –
1) By Type: Sympathetic Paragangliomas, Parasympathetic Paragangliomas, Caroid Paragangliomas, Cervical Paragangliomas, Jugular Paragangliomas, Secretory Paragangliomas, Temporal Paragangliomas
2) By Origin: Head And Neck, Abdomen, Pelvis, Other Origins
3) By Treatment Type: Peptide Receptor Radionuclide Therapy, Surgery, Chemotherapy, Radiation Therapy, Other Treatment Types
4) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes, Other End-Users
Subsegments:
1) By Sympathetic Paragangliomas: Adrenal Sympathetic Paragangliomas, Extra-Adrenal Sympathetic Paragangliomas
2) By Parasympathetic Paragangliomas: Head And Neck Parasympathetic Paragangliomas, Thoracic Parasympathetic Paragangliomas
3) By Carotid Paragangliomas: Unilateral Carotid Paragangliomas, Bilateral Carotid Paragangliomas
4) By Cervical Paragangliomas: Vagal Paragangliomas, Hypoglossal Paragangliomas
5) By Jugular Paragangliomas: Type A, Type B, Type C, Type D
6) By Secretory Paragangliomas: Catecholamine-Secreting Paragangliomas, Non-Catecholamine-Secreting Paragangliomas
7) By Temporal Paragangliomas: Tympanic Paragangliomas, Mastoid Paragangliomas
What Are the Latest Trends in the Paraganglioma Market?
Leading entities in the paraganglioma market are honing in on the creation of advanced therapies, such as oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitors, to provide more precise treatment for paraganglioma patients. Oral HIF-2α inhibitors are expressly designed to curb HIF-2α activity, a pivotal component in tumor development in areas with low oxygen, thus helping to limit the advancement of cancers, including paraganglioma. For example, in January 2025, US biopharmaceutical leader Merck announced that the U.S. Food and Drug Administration (FDA), a government agency, had fast-tracked the review for their supplemental new drug application for Welireg (belzutifan). This drug is conceived for adult and pediatric patients aged 12 years and above diagnosed with advanced, inoperable, or metastasized pheochromocytoma and paraganglioma (PPGL). The application is founded on objective response rate (ORR) and duration of response (DOR) data from the Phase 2 LITESPARK-015 trial.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/paraganglioma-global-market-report
What Are the Key Regional Markets in the Paraganglioma Industry?
North America was the largest region in the paraganglioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paraganglioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21245
This Report Delivers Insight On:
1. How big is the paraganglioma market, and how is it changing globally?
2. Who are the major companies in the paraganglioma market, and how are they performing?
3. What are the key opportunities and risks in the paraganglioma market right now?
4. Which products or customer segments are growing the most in the paraganglioma market?
5. What factors are helping or slowing down the growth of the paraganglioma market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model